Albutrepenonacog Alfa 1 UNT
ApprovedSmall molecule
Albutrepenonacog Alfa 1 UNT is one of 20 small molecule programs targeting Hemophilia B. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Hemophilia B
#DrugCompanyPhaseTrials
1Recombinant Factor IX Coagulation
PfizerApproved
IB1001
MMedexus Pharma, Inc.
Phase 3
Translarna
PPTC Therapeutics
Phase 2
Albutrepenonacog Alfa 1 UNT
NNational Taiwan University Hospital
Approved
BENEFIX
PfizerPhase 3
Recombinant Factor IX
BBaxalta now part of Shire
Phase 3
Rfix
PfizerPhase 3
Factor Ix
CSL BehringPhase 3
Nonacog Alfa
PfizerPhase 3
Rix-FP
CSL BehringPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Albutrepenonacog Alfa 1 UNT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details